ym 872 has been researched along with Disease Models, Animal in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anraku, T; Asano, J; Hori, W; Shiga, F; Takano, Y; Uno, T | 1 |
| Bartlett, CA; Chiha, W; Fitzgerald, M; Giacci, MK; Harvey, AR; Hodgetts, SI; O'Hare Doig, RL; Smith, NM; Yates, NJ | 1 |
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
| Aihara, M; Ishiuchi, S; Ohtani, T; Watanabe, T | 1 |
| Kawasaki-Yatsugi, S; Kohara, A; Ni, JW; Okada, M; Sakamoto, S; Shimizu-Sasamata, M; Shishikura, J; Takahashi, M; Yamaguchi, T; Yatsugi, S | 1 |
| Hara, H; Kodama, M; Kuroda, S; Matsumoto, Y; Wake, Y; Yamada, N | 1 |
| Ichiki, C; Kawasaki-Yatsugi, S; Minematsu, K; Shimizu-Sasamata, M; Takahashi, M; Toya, T; Yamaguchi, T; Yatsugi, S | 1 |
1 review(s) available for ym 872 and Disease Models, Animal
| Article | Year |
|---|---|
YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
Topics: Animals; Brain Ischemia; Cats; Clinical Trials, Phase I as Topic; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Imidazoles; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Quinoxalines; Rats; Receptors, AMPA; Solubility; Stroke | 2002 |
6 other study(ies) available for ym 872 and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Imidazoles; In Vitro Techniques; Infusions, Intravenous; Neuroprotective Agents; Quinoxalines; Rats; Receptors, AMPA; Solubility; Structure-Activity Relationship | 2004 |
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal; Female; Imidazoles; Macrophages; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Optic Nerve Injuries; Oxidative Stress; Piperazines; Purinergic P2X Receptor Antagonists; Quinoxalines; Random Allocation; Ranvier's Nodes; Rats; Receptors, AMPA; Receptors, Purinergic P2X7 | 2017 |
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |
Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Glioblastoma; Humans; Imidazoles; In Vitro Techniques; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Quinoxalines; Receptors, AMPA; Receptors, Platelet-Derived Growth Factor; Transplantation, Heterologous; Treatment Outcome; Tyrphostins | 2013 |
Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Imidazoles; Kindling, Neurologic; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2006 |
A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
Topics: Animals; Arterial Occlusive Diseases; Blood Gas Analysis; Body Temperature; Brain; Brain Ischemia; Cerebral Arteries; Cerebral Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Infusions, Intravenous; Kidney; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 1998 |